Paradigm Biocapital Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Paradigm Biocapital Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$144M	Buy	+480,000	New	+$145M	2.71%	12

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Paradigm Biocapital Advisors's ALNY Position: Q2 2026 in Review

Paradigm Biocapital Advisors opened a new position in Alnylam Pharmaceuticals (ALNY) in Q2 2026: 480,000 shares worth $144M. The stake represents 2.71% of the portfolio and ranks #12 among its holdings.

784 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

Paradigm Biocapital Advisors held 480,000 shares of Alnylam Pharmaceuticals worth $144M as of Q2 2026.
Alnylam Pharmaceuticals was a new Paradigm Biocapital Advisors position in Q2 2026.
Alnylam Pharmaceuticals made up 2.71% of Paradigm Biocapital Advisors's portfolio in Q2 2026, its #12 holding.
784 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Paradigm Biocapital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.